MTOR and lymphangioleiomyomatosis: No significant difference in Gal-3 levels was observed between patients with LAM not taking mTOR inhibitor (4649 ± 1980 pg/mL, n = 64) and normal subjects (5023 ± 1646 pg/mL, n = 25).